Management of Chemotherapy-Induced Neutropenia in Adult Cancer Patients
Risk Stratification and Prophylaxis
- The National Comprehensive Cancer Network (NCCN) recommends risk-stratified prophylaxis with fluoroquinolones for high-risk patients (expected severe neutropenia ≥7 days) 1, 2
- High-risk patients include those with expected severe neutropenia (ANC <500/μL) lasting ≥7 days, profound neutropenia (ANC <100/μL) expected for ≥2 weeks, acute leukemia induction/consolidation with anticipated neutropenia >10 days, high-dose chemotherapy followed by autologous hematopoietic cell transplantation, and chemotherapy regimens with >20% risk of febrile neutropenia 1, 3, 4
- Intermediate-risk patients include those with expected neutropenia duration <7 days with patient risk factors (age >65, prior febrile neutropenia, poor performance status, advanced disease) and chemotherapy regimens with 10-20% risk of febrile neutropenia 3
- Low-risk patients include those with expected brief neutropenia with no additional risk factors and chemotherapy regimens with <10% risk of febrile neutropenia 3
Prophylactic Antibacterial Therapy
- The NCCN recommends initiating fluoroquinolone prophylaxis when neutropenia develops (not before chemotherapy) and continuing until neutrophil recovery to 500-1000/μL 1, 4
- Preferred regimen is levofloxacin 500-750 mg orally once daily due to superior gram-positive coverage compared to ciprofloxacin 4, 5
- Alternative regimens include ciprofloxacin 500-750 mg orally every 12 hours and trimethoprim-sulfamethoxazole (TMP-SMX) 800/160 mg orally three times weekly when concurrent Pneumocystis prophylaxis is indicated 4, 5
Granulocyte Colony-Stimulating Factor (G-CSF) Administration
- The NCCN recommends administering G-CSF starting 24 hours after chemotherapy completion and continuing until ANC reaches 10,000/mm³ following the expected nadir 3
- Indications for G-CSF include primary prophylaxis in high-risk patients (>20% febrile neutropenia risk) receiving chemotherapy with curative or life-prolonging intent, secondary prophylaxis in patients who experienced febrile neutropenia or dose-limiting neutropenic events in prior cycles, and therapeutic use in febrile neutropenic patients with high-risk features (pneumonia, hypotension, multiorgan dysfunction, fungal infection) 3, 6, 7
- There is Category 1 evidence that G-CSF reduces the risk of febrile neutropenia, hospitalization, and IV antibiotic use, but evidence for reduction in infection-related mortality is Category 2A (less robust) 3
Comprehensive Antimicrobial Prophylaxis Package
- The NCCN recommends a complete prophylaxis bundle, including antibacterial, antiviral, antifungal, and Pneumocystis coverage, for high-risk neutropenic patients 7, 4, 5
- Antiviral prophylaxis (HSV/VZV) includes acyclovir 400-800 mg orally twice daily or valacyclovir 500 mg orally twice daily, starting with chemotherapy and continuing during neutropenic periods 7, 4, 5
- Pneumocystis jirovecii prophylaxis includes TMP-SMX 800/160 mg (double strength) orally three times weekly, continuing until CD4+ count ≥200 cells/μL for ≥3 months post-chemotherapy (minimum 2-3 months) 7, 4, 5
- Antifungal prophylaxis includes fluconazole 400 mg orally daily during prolonged neutropenia (≥7 days), starting on day of cell infusion (for transplant patients) or when severe neutropenia begins, and continuing until ANC >1000/mm³ 7, 4, 5
Management of Febrile Neutropenia
- The NCCN recommends initiating broad-spectrum IV antibiotics within 2 hours of fever development in neutropenic patients, with a regimen that includes vancomycin plus an antipseudomonal agent (cefepime, carbapenem, or piperacillin-tazobactam) 1, 2, 5
- Diagnostic workup includes obtaining at least two sets of blood cultures before starting antibiotics, complete blood count and platelet count, chest radiograph, urinalysis and urine culture, and stool evaluation if diarrhea is present 2, 8
- Therapeutic G-CSF consideration includes adding G-CSF in high-risk febrile neutropenia with pneumonia, hypotension, multiorgan dysfunction, or fungal infection 6, 7, 2
Special Consideration: Neutropenic Enterocolitis
- The NCCN recommends aggressive medical management for neutropenic enterocolitis, including broad-spectrum antibiotics, G-CSF administration, nasogastric decompression, IV fluids, and bowel rest 8
- Surgical indications include persistent GI bleeding despite platelet/coagulation correction, free intraperitoneal perforation, abscess formation, or clinical deterioration despite aggressive medical management 8